Spectral Medical Inc. Provides Tigris Clinical Trial Update

Recruitment activity returning to normalized levels with 12 trial sites actively screening patients 15 sites on track to open for enrollment by the end of Q3 2021 TORONTO, July 28, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage...
Read More

Spectral Medical Inc. Announces $10 Million Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario | July 21, 2021 – Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce that further to its previously announced...
Read More

Spectral Medical Inc. Announces Overnight Marketed Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario | July 20, 2021 – Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce the launch of a proposed overnight marketed...
Read More
Click to Hide Advanced Floating Content
EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.